Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00625573 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)
A Phase 2 study, sponsored by Mt. Sinai Medical Center, Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00625573 is a Phase 2 study that has completed, run by Mt. Sinai Medical Center, Miami. The registered enrollment target is 29 participants.
The verdict
NCT00625573, a Phase 2 study, has completed, sponsored by Mt. Sinai Medical Center, Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is an open-label, phase II study to evaluate the efficacy and safety of Abraxane in combination with Capecitabine in patients with metastatic colorectal cancer in the second or third line
Interventions
- DRUG Abraxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00625573
The ClinicalTrials.gov registry entry for NCT00625573 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mt. Sinai Medical Center, Miami, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abraxane is the first listed.
NCT00625573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00625573 about?
NCT00625573 is a clinical study titled "Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)". This is an open-label, phase II study to evaluate the efficacy and safety of Abraxane in combination with Capecitabine in patients with metastatic colorectal cancer in the second or third line
What is the current status of trial NCT00625573?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2007-09. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00625573?
The interventions under investigation include: Abraxane (DRUG).
Who is sponsoring clinical trial NCT00625573?
This trial is sponsored by Mt. Sinai Medical Center, Miami, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.